ClearNote Health

📢 We are pleased to announce that the American Medical Association CPT® has issued ClearNote Health our second Proprietary Laboratory Analysis code, the newest being issued for the Avantect Ovarian Cancer Test. The Avantect Ovarian Cancer test is intended for use in women with suspicion of ovarian cancer, including patients at high risk for the disease, such as women with a genetic predisposition to ovarian cancer as defined by NCCN guidelines, a family history of ovarian cancer or personal history of breast cancer.    According to the ACS, only 20% of ovarian cancers are found early stage, and when found early, the 5-year post-diagnosis survival rate jumps to 94%. New technology will change the way we detect and diagnose cancer in high-risk patients, such as those with a genetic predisposition or family history of cancer. Our dedication to early detection and enabling longer, healthier lives is shared by many in the oncology community. It will take all of us to make a difference in mortality rates.

Don't miss our team at the American Diabetes Association's 84th Scientific Sessions, taking place in Orlando, FL, June 21-24! #pancreaticcancer #ADAscisessions #diabetes

Visit our booth (30149) this weekend at #ASCO24 to learn about our partnership with ClearNote Health. Through our agreement, we will distribute ClearNote’s Virtuoso platform, a blood-based epigenomics platform, to complement our pharmaceutical service offerings. Virtuoso complements our ImmunoID NeXT® and NeXT Personal® tissue and blood-based product portfolio by: - Identifying patients more likely to benefit from the drug treatment - Allowing for non-invasive longitudinal monitoring of patients’ drug response - Providing dynamic insights into therapy response and resistance — all through a simple blood draw Discover more about our partnership here: https://bit.ly/495d2Do. #PrecisionOncology #Genomics #Epigenomics

❓ What do you consider is the main challenge in drug development and translational research? 🎓 Take part in our survey below and let us know!   ClearNote Health is dedicated to optimising drug development and discovery with our Virtuoso epigenomic platform that measures active disease biology to provide dynamic insights into therapy response and resistance - all through a simple blood draw. Attending #ASCO? Contact us at ASCO2024@clearnotehealth.com to set up a time to meet in person at the event. #drugdevelopment #drugdiscovery

📢 Our team will be attending #ASCO 2024!   ClearNote Health’s Virtuoso #epigenomics platform is a groundbreaking, non-invasive, whole genome sequencing and 5hmC enrichment solution designed to revolutionize translational research by revealing active disease biology and empowering #drugdiscovery and development.   ✅ Virtuoso can: 1. Identify patients more likely to benefit from the drug treatment 2. Allow for non-invasive longitudinal monitoring of patients’ drug response 3. Provide dynamic insights into therapy response and resistance And the best part? All these dynamic insights into therapy response and resistance can be obtained through a simple blood draw, making the process easy and convenient for both patients and researchers.   👉 Contact us at ASCO2024@clearnotehealth.com to set up a meeting or visit our partner Personalis, Inc.’s booth #30149 to discover how we can help you improve your #drugdevelopment process.

🌍 On May 17, 2024, ClearNote Health's CEO Dave Mullarkey traveled to Athens, Greece, solidifying our commercial partnership with GeneKor Medical S.A. to advance the field of early cancer detection. 👋 Hosted by Nikolaos Tsoulos of Genekor, our discussions centered on the rollout of the Avantect Pancreatic Cancer Test across multiple EU countries. This innovative diagnostic solution is poised to enhance early detection of pancreatic cancer in key Genekor territories.   👨⚕️During our visit, Dave also engaged with local Key Opinion Leaders to align on the best approaches to integrate this technology into their medical practice and healthcare systems effectively.   🤝This partnership underscores our shared commitment to pioneering advancements in healthcare and to significantly improving patient outcomes through state-of-the-art diagnostics.   We are inspired by the potential of our collaboration with Genekor and eagerly anticipate the impact our combined efforts will have on transforming cancer care globally. #earlycancerdetection #pancreaticcancer

Join us at Digestive Disease Week® (DDW) in Washington, DC, from May 18th to 21st, 2024!    Don't miss an insightful presentation by our Vice President, Product Development, Anna Bergamaschi:   📜 Title: Detection of High-Risk Pancreatic Cysts Using Avantect™ Blood-Based Test Abstract: #4040568 Session: Pancreatic Cystic Neoplasms, IPMN and Neuroendocrine Tumors (Clinical) 📍 Location: Hall A, Poster Hall (Walter E. Washington Convention Center) 📅 When: May 21, 2024, 12:30-1:30PM Avantect is a DNA-based blood test designed to make earlier diagnosis possible for patients at high risk for pancreatic cancer. Not attending the event, but wish to learn more? Contact us at https://lnkd.in/dp-yahs9 or visit the Avantect website: https://www.avantect.com/   #DDW2024 #Pancreaticcancer

🚨 Highlight from Abu Dhabi Global Health Week: Liquid Biopsy for Early Cancer Detection 🎤 At the Abu Dhabi Global Healthcare Week Week, Dave Mullarkey, CEO of ClearNote Health, showcased the groundbreaking Avantect Pancreatic Cancer Test. 🔈In a panel discussion led by Dr. Lawrence P Petalidis of M42 he focused on the test’s use of liquid biopsy technology for early detection in high-risk patients, including those recently diagnosed with Type 2 diabetes. 🌟 Highlighting the test’s potential, Dave illustrated how Avantect significantly enhances early cancer detection, offering advantages over traditional methods and paving the way for significantly increasing survival rates in pancreatic cancer. 🤝 The session was a clear testimony of how M42 Health, supported by the Department of Health Abu Dhabi and in close clinical collaboration with Cleveland Clinic Abu Dhabi, is pioneering advancements in oncology, driving the next generation of cancer diagnostics. #ADGHW #CancerDiagnostics #HealthcareInnovation #LiquidBiopsy

📣 📰 Exciting news from ClearNote Health! Our Avantect Pancreatic Cancer Test has been featured in an expert article on pancreatic cancer published in The Telegraph, one of the UK's leading newspapers. As noted in the article, pancreatic cancer remains one of the most challenging cancers to diagnose early and treat due to its aggressive nature and complex biological environment. Avantect is featured as a new generation of diagnostic test that offers a groundbreaking approach to early detection by picking up early signs of pancreatic cancer through detecting changes in the blood. This is crucial as pancreatic cancer often shows no symptoms in its early stages, making early detection key to improving survival rates.  Thank you to Dr David Cox for highlighting pancreatic cancer as a critical area of healthcare with vast unmet medical need. 👉 Read the article here: https://lnkd.in/dvsTf_Yx (paywall) 👉 For more information on how Avantect is changing the landscape of cancer detection, visit our website or contact us: https://www.avantect.com/ #PancreaticCancerAwareness #EarlyDetectionSavesLives #PancreaticCancer

🌍 📢 We are excited to announce that Dave Mullarkey, CEO of ClearNote Health, will be attending Abu Dhabi Global Healthcare Week. Join him as he delves into the latest advancements in healthcare innovation and genomics. 🗓️ Dave will be participating in a panel on liquid biopsy technologies, organized by M42 Health, on Monday, May 13th. M42 is a leading force in driving healthcare innovation in the region, and we're eager to contribute to the discussions. Stay tuned for more details! 🤝 If you're attending the conference, we'd love to connect with you to explore the future of healthcare innovation. Contact us at: https://lnkd.in/dp-yahs9 #AbuDhabiGlobalHealthWeek #HealthcareInnovation #Genomics #LiquidBiopsy